We use cookies. Read morehereI UNDERSTAND Member pages / Intranet Press plug In English News Issues we work with Basic facts Statistics Ethics Calendar About LIF Home News Cost-neutral proposal can still be experienced as a price increase Cost-neutral proposal can still be experienced as a price increase DECEMBER 15, 2015 The Swedish Dental and Pharmaceutical Benefits Agency, TLV, proposes "changed trading margins" for pharmacies. The results of the proposals may be perceived by county councils and regions as making the prices of the most expensive medicines even higher - up to a price increase of SEK 900. This will be the most visible effect of a proposal which in its entirety is intended to be cost-neutral. But LIF believes that it is TLV's responsibility to clarify that it is not the pharmaceutical companies that raise the prices of the already expensive drugs, but that it is the pharmacies that have both demanded and now receive increased compensation for selling more expensive drugs. The redistribution of the pharmacies' trading margin also affects the pharmaceutical companies in several other areas, which LIF considers to be insufficiently investigated and analyzed. Read the entire LIF consultation response via the link below. LIF letter to the government about shortcomings in TLV's proposal Vissa av de brister LIF pekar på i remissvaret till TLV ser vi som extra allvarliga. Det gäller vissa tekniska beräkningsgrunder av priserna, som enligt LIF:s uppfattning har en "direkt och omfattande affärsmässig påverkan på företagen", trots att TLV i sitt förslag påstår att de inte har det. Med anledning av dessa briser har LIF även riktat en separat skrivelse till både Socialdepartementet och TLV där vårt krav är att TLV inför kommande trepartsöverläggningar finner en avtalsmodell där framtida justeringar av handelsmarginalen för apoteken inte påverkar läkemedelsföretagen ekonomiskt. LIF begär också snabbt svar på denna skrivelse. Läs skrivelsen via separat länk nedan. Relaterat innehåll Remissvar: Förslag till ändring av Tandvårds- och Läkemedels-förmånsverkets föreskrifter om handelsmarginal Letter due to: Proposal to amend the Swedish Dental and Pharmaceutical Benefits Agency's regulations More from LIF Quick navigation plug Member pages Order / download material Referral response Cookie Policy LIF's Data Protection Policy Navigation News Issues we work with Basic facts Statistics Ethics Press Calendar About LIF